Alerje
Founded 2016 · 7 employees on LinkedIn · 6 known investors
Alerje develops FAIT, a mobile app and clinical platform for food allergy oral immunotherapy (OIT), offering dose tracking, HIPAA-compliant clinic messaging, and predictive insights. It serves families managing childhood food allergies and the allergy clinics coordinating their care.
Founders & leadership
Alerje was founded in 2016 by Javier Evelyn.
JE
Javier EvelyninFounder & CEO
Investors · 6
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2023 | $1M |
| National Science Foundation | Phase I | 2021 | $255.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Alerje do?
- Alerje develops FAIT, a mobile app and clinical platform for food allergy oral immunotherapy (OIT), offering dose tracking, HIPAA-compliant clinic messaging, and predictive insights. It serves families managing childhood food allergies and the allergy clinics coordinating their care.
- Who founded Alerje?
- Alerje was founded by Javier Evelyn in 2016.
- Who are Alerje's investors?
- Alerje's investors include Backstage Capital, Chloe Capital, ID Ventures, Jumpstart Nova, Michigan Rise, Seae Ventures.